Yimin Pharma -B (01541): The first patient has been dosed in the Phase II/III clinical trial of IMM0306 for the treatment of IgG4-related diseases.

CapitalVille Finance APP News, Yi Ming Aung-B (01541) announced that the II/III phase trial of IMM0306 for the treatment of IgG4-related diseases (IgG4-RD) has successfully completed dosing for the first patient. IgG4-RD is a chronic, progressive fibroinflammatory disease that may affect multiple organ systems, including the pancreas, bile ducts, salivary glands, lacrimal glands, and retroperitoneal tissues. In severe cases, the disease can lead to organ failure. Current immunosuppressive therapies are still limited by low response rates and high recurrence rates. Inebilizumab (an anti-CD19 monoclonal antibody) is currently the only approved biologic therapy, but there are still many unmet clinical needs. Studies have shown that abnormal activation of B cells and IgG4-positive plasma cell infiltration are the core pathogenic mechanisms of IgG4-RD, which closely match the mechanism of action of IMM0306.